Is gluten intolerance just a passing trend? The gluten-free diet has exploded in popularity, with gluten-free products now ubiquitous on supermarket shelves. Yet celiac disease—an autoimmune disorder triggered by gluten in wheat, barley, and rye—affects only about 1% of people. So why do so many others report feeling better after cutting out gluten? Researchers at Columbia University delved into this question.
A study from Columbia University, published on July 25, 2016, in the journal Gut, confirmed gluten sensitivity through a specific cellular marker. The team analyzed 160 participants: 40 with celiac disease, 80 with non-celiac gluten sensitivity (NCGS), and 40 healthy controls. They estimate NCGS affects around 1% of the population.
To pinpoint the marker, researchers examined responses to gluten intake. Celiac patients experience gut-specific symptoms like abdominal pain, diarrhea, and bloating, with immune reactions confined to the small intestine. In contrast, those with NCGS face broader issues: gastrointestinal distress plus fatigue, brain fog, and mood changes. Crucially, NCGS patients showed elevated levels of FABP2—a marker of intestinal epithelial cell damage—and a more permeable gut barrier, triggering systemic immune responses. Encouragingly, after six months on a gluten-free diet, FABP2 levels normalized, symptoms improved dramatically, and the gut barrier strengthened. Detecting FABP2 could enable precise NCGS diagnosis and targeted treatments. Stay tuned for more developments.
